What We Do

  • Development of CDx
  • Pharma portfolio management
  • Drug repurposing
  • Uptiering
  • Patient selection/enrichment

  • 10,000s of Human autoantibody profiles
  • Multi-ethnic samples
  • True positive samples from various diseases

  • Develop sero-diagnostics
  • License diagnostics IP for cancer, autoimmune disorders and neurodegenerative conditions
  • Discover new diagnostic IP

Sengenics measures autoantibodies at unrivalled sensitivity and specificity

UPCOMING EVENTS

JANUARY 13 – 16, 2020

KREX TECHNOLOGY

KREX™ utilises the BCCP folding marker to actively select for soluble, correctly folded, functional proteins

PARTNERING

Engage in innovative research, discovery and development through active long-term collaborations with us

FEATURED PRODUCTS

IMMUNOME
Protein Array

High-throughput
sero-profiling platform

CTA
Protein Array

Screening of
cancer-testis antigens

OncoREX p53
Cancer Array

Cancer drug
screening and discovery

Custom
Protein Array

Flexible format for
high-throughput screening

DOWNLOADS

Resources to access our technology

FAQs

Your technical questions – answered

SOLUTIONS

One technology – endless possibilities

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2019 © Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

2008 – 2019 © Sengenics All rights reserved 

X